Abraxis Bioscience - Biotech's Biggest Spenders
Based: Abraxis Bioscience
R&D budget: $146 million (€107M)
Change from 08: +49.3%
Income spent on R&D: 43.1%
You won't see Abraxis on next year's list. As we noted, Celgene bought out Abraxis for $2.9 billion earlier this year. Celgene's gamble is that it can make more money, a lot more money, with Abraxane as it picks up the work on expanding its use. This is one more R&D budget that is being absorbed inside another company.
Comments